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 2 
Abstract 20 
There is an urgent need for safe, efficacious, affordable and field-adapted drugs for the 21 
treatment of cutaneous leishmaniasis which affects around 1.5 million new people 22 
worldwide annually.  Chitosan, a biodegradable cationic polysaccharide, has previously 23 
been reported to have antimicrobial, anti-leishmanial and immunostimulatory activities. 24 
We investigated the in vitro activity of chitosan and several of its derivatives and showed 25 
that pH of the culture medium plays a critical role on anti-leishmanial activity of chitosan 26 
against both extracellular promastigotes and intracellular amastigotes of Leishmania 27 
major and Leishmania mexicana.  Chitosan and its derivatives were approximately 7-20 28 
times more active at pH 6.5 than at pH 7.5 with high molecular weight chitosan being 29 
the most potent. High molecular weight chitosan stimulated the production of nitric oxide 30 
and reactive oxygen species by uninfected and Leishmania infected macrophages in a 31 
time and dose dependent manner at pH 6.5. Despite the in vitro activation of bone 32 
marrow macrophages by chitosan to produce nitric oxide and reactive oxygen species, 33 
we showed that the anti-leishmanial activity of chitosan was not mediated by these 34 
metabolites. Finally, we showed that rhodamine-labelled chitosan is taken up by 35 
pinocytosis and accumulates in the parasitophorous vacuole of Leishmania infected 36 
macrophages.  37 
KEYWORDS: Cutaneous leishmaniasis, Leishmania major, Leishmania mexicana, 38 
chitosan, macrophage uptake. 39 
40 
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 3 
Introduction 41 
Leishmaniasis is an infectious disease caused by protozoan parasites belonging to the 42 
genus Leishmania. The parasite is transmitted between humans and mammalian 43 
reservoirs (e.g. dogs and rodents) through the bite of a female phlebotomine sandfly (1). 44 
There are two main clinical forms, cutaneous leishmaniasis (CL) and visceral 45 
leishmaniasis (VL), with CL being the most common (2). In addition to “simple” CL, there 46 
are other complex cutaneous manifestations including mucocutaneous leishmaniasis 47 
(MCL), diffuse cutaneous leishmaniasis (DCL), recidivans leishmaniasis (RL) and post-48 
kala-azar dermal leishmaniasis (PKDL) (3, 4). 49 
 CL is caused mainly by Leishmania tropica, Leishmania major and Leishmania  50 
aethiopica in the Old World and by Leishmania braziliensis, Leishmania guyanensis, 51 
Leishmania mexicana  and Leishmania amazonensis in the New World(5). Of the 88 52 
countries where CL occurs, 90% of the cases are in Afghanistan, Brazil, Iran, Peru, 53 
Saudi Arabia and Syria (1). In the mammalian host, the parasite survives and multiplies 54 
within macrophages. The cellular immune responses in CL play a critical role in the 55 
control and progress of the disease, which include two main mechanisms of 56 
macrophage activation: (i) the classical pathway (M1 macrophages) in which Th1 and 57 
NK cells produce cytokines (such as IFN-γ) which stimulate the production of nitric oxide 58 
(NO) and reactive oxygen species (ROS) and the activation of other lysosomal anti-59 
microbial activities which are responsible for killing the Leishmania parasites and (ii) the 60 
alternative pathway mediated by Th2 cytokines, such as IL-4 and IL-13 in the early 61 
stages of infection forming a favourable environment for Leishmania proliferation (6, 7).  62 
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 4 
Pentavalent antimonial compounds,  sodium stibogluconate (Pentostam ®) and 63 
meglumine antimoniate (Glucantime®), have been the standard treatment for CL for the 64 
past 70 years (8). These drugs have several limitations including difficulty of 65 
administration, toxicity of the drug and variable sensitivity among Leishmania species 66 
(9). Second-line treatments include the polyene antifungal amphotericin B which also 67 
suffers from toxicity, the oral phospholipid miltefosine, the use of which is limited by 68 
teratogenicity, and the aminoglycoside antibiotic paromomycin (PM) which has low cure 69 
rates for certain Leishmania species (10, 11, 12). Treatment with intravenous 70 
AmBisome® (liposomal amphotericin B ) is safe and has achieved clinical success at a 71 
dose of 3 mg/kg daily for 7 days against CL(13, 14) but the high cost of this formulation 72 
limits its use (15). Two Cochrane analyses have clearly shown clinical deficiencies of 73 
most drugs.  There is an urgent need for new treatments which can eliminate the 74 
parasites, improve the healing process, are safe, reliable and also field-adaptable for 75 
use in diverse health care systems (16, 17).  76 
Chitosan is a biodegradable, biocompatible, positively charged non-toxic muco-77 
adhesive biopolymer produced by the deacetylation of chitin. Chitosan has a pKa of 78 
approximately 6.3, is insoluble at alkaline pH but soluble in weak acidic solvents like 79 
acetic acid where the amino groups become protonated.  Many reports have described 80 
the antimicrobial activity of chitosan but the actual mechanism of action has not been 81 
fully elucidated (18) although three direct mechanisms have been suggested. The first is 82 
the interaction between the protonated NH3+ groups of chitosan and the negative cell 83 
membrane of microbes. This interaction changes the permeability of the microbial cell 84 
membrane, causing osmotic imbalances, and consequently killing them (18, 19).  The 85 
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 5 
second suggested mechanism is that chitosan binds to microbial DNA and inhibits DNA 86 
transcription, assuming that chitosan penetrates the microbial cell membrane and 87 
reaches the DNA (19, 20). The third mechanism is via the chitosan chelation of metals 88 
and the binding of basic nutrients essential for microbial growth (19). An indirect 89 
mechanism of action may be related to the known pro-inflammatory effect of chitosan on 90 
macrophages. This involves stimulation of tumour necrosis factor (TNF-α), interleukin 6 91 
(IL-6), NO, ROS and interferon gamma (IFN-γ) which play a critical roles in the 92 
proinflammatory response against intracellular microbes (by enhancing the production 93 
of microbicidal reactive nitrogen species) (21, 22, 23, 24, 25). Chitosan activates 94 
polymorphonuclear leukocytes, macrophages and fibroblasts and these properties 95 
promote wound healing (18, 26). 96 
The poor solubility of chitosan and the loss of the cationic charge at neutral 97 
and alkaline environments are two of the major obstacles to the consideration of 98 
chitosan as a useful antimicrobial. Recently, the chemical modification of chitosan to 99 
produce various derivatives to improve its solubility and widen its application has gained 100 
attention (27) (28). Chitosan and its derivatives have been shown to have in vitro anti-101 
leishmanial activity with EC50 values (50% effective concentration) ranging from 70 to 102 
240 μg/ml against L. infantum, L. amazonensis and L. chagasi promastigotes and 103 
amastigotes (29, 30, 31, 32, 33, 34). All this makes chitosan an appropriate candidate 104 
for further studies to evaluate its suitability for the treatment of CL.  105 
The aim of our work was to:  (i) determine the in vitro anti-leishmanial activity of chitosan 106 
and its derivatives against L. major and L. mexicana promastigotes and intracellular 107 
amastigotes at two different pH values (the culture medium pH of 7.5 and a lower pH of 108 
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 6 
6.5, which are both suitable for macrophage and parasite growth(35, 36, 37), (ii) to 109 
evaluate the in vitro role of chitosan in the activation of macrophage M1 proinflammatory 110 
phenotype, via the measurement of NO ,ROS and TNF-α production by host cells and 111 
by measuring parasite survival, and (iii) investigate chitosan uptake by macrophages to 112 
explain its activity against intracellular amastigotes.  113 
114 
 o
n
 January 7, 2020 at LO
NDO
N SCHO
O
L O
F HYG
IENE & TRO
PICAL M
EDICINE
http://aac.asm
.org/
D
ow
nloaded from
 
 7 
Results 115 
 116 
In vitro activities of chitosan and derivatives against L. major and L. mexicana. 117 
Anti-leishmanial activity (against promastigotes and amastigotes) of high, medium and 118 
low molecular weight (HMW, MMW and LMW respectively) chitosan and its derivatives 119 
(a total of 11) was tested. Dose dependent activity (Fig S1 and S2) against Leishmania 120 
promastigotes and amastigotes was observed for chitosan and its’ derivatives except for 121 
carboxymethyl chitosan which showed no activity against either parasite stage within 122 
the experimental parameters tested (pH 7.5 or 6.5 and concentrations up to 400 µg/ml). 123 
In the 72 h assays, chitosan and its derivatives (except carboxymethyl chitosan) were 7-124 
20 times more active against L. major and L. mexicana promastigotes and intracellular 125 
amastigotes (infecting peritoneal mouse macrophages (PEMs)) in culture medium at 126 
pH=6.5 than at pH=7.5 (p<0.05 by t-test) (Tables 1 and 2). HMW, MMW and LMW 127 
chitosan, from both crustacean and fungal sources, exhibited significantly higher 128 
activities against promastigotes and intracellular amastigotes (EC50 ≈ 6 µg/ml against L. 129 
major promastigotes and 10 µg/ml against L. mexicana promastigotes; EC50 ≈ 12 µg/ml 130 
against L. major amastigotes and 16 µg/ml against L. mexicana amastigotes) than the 131 
derivatives at pH= 6.5 (Tables 1 and 2) (p<0.05 by an extra sum-of-squares F test). 132 
Additionally, L. major promastigotes and amastigotes were significantly more sensitive 133 
to chitosan and its derivatives than L. mexicana promastigotes and amastigotes 134 
(approx. 1.5 to 2 times, p<0.05 by an extra sum-of-squares F test). 135 
To allow like-for-like comparison, EC50 values were recalculated in terms of molarity 136 
using estimated molecular weights (HMW: MW= 342.5 KDa, MMW: MW=250 KDa, 137 
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 8 
LMW: MW= 120 KDa and fungal chitosan MW=130 KDa) at pH = 6.5. Based on molarity 138 
(Table S4 and S5), HMW chitosan was significantly more active against L. major and L. 139 
mexicana promastigotes and amastigotes and hence used in all subsequent studies.  140 
 141 
Host cell dependence of the anti-leishmanial activity of HMW chitosan at pH 6.5  142 
We aimed to assess the host cell dependence of the anti-leishmanial activity of HMW 143 
chitosan and Fungizone by evaluating the in vitro activity against L. major amastigotes 144 
in three different macrophage type; EC50 and EC90 values in the three different 145 
macrophage populations are summarized in Table 3. There was a significant difference 146 
in the activity of HMW chitosan depending on the type of macrophage; PEMs, bone 147 
marrow-derived macrophages (BMMs) or human leukaemic monocytes-like derived cell 148 
line (THP-1)) (p<0.05 by an extra sum-of-squares F test). HMW chitosan was 149 
significantly more active against intracellular amastigotes in PEMs and BMMs compared 150 
to differentiated THP-1 cells. 151 
 152 
Effects of HMW chitosan on the production of TNF-α by uninfected or L. major 153 
infected BMMs at pH = 6.5 154 
The activation of M1 macrophages by Th1 lymphocyte plays an important role in the 155 
control of CL (6, 38, 39). Therefore, we measured TNF-α production by BMMs 156 
stimulated by HMW chitosan. Following exposure to HMW chitosan, the TNF-α 157 
production by BMMs was found to be dose-dependent, in a bell-shaped manner, in both 158 
Leishmania-infected and uninfected cells as shown in Fig. 1. After 24 h, the levels of 159 
TNF-α in the culture fluid of BMMs exposed to HMW chitosan (at concentrations 14.8, 160 
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 9 
44.4 and 133.3 µg/ml) was significantly higher than BMMs (infected and uninfected), 161 
that had not been exposed to chitosan with TNF- α being highest at 44.4 µg/ml chitosan. 162 
While at other concentrations (1.64, 4.9 and 400 µg/ml), HMW chitosan did not 163 
stimulate BMMs to produce TNF-α (p < 0.05 by t-test). 164 
 HMW chitosan at concentrations 14.8, 44.4 and 133.3 μg/mL stimulated BMMs to 165 
produce TNF-α with 87± 4.5 - 712± 9 - 48±3 pg/ml respectively in uninfected BMMs and 166 
56± 3.5 - 464± 10 - 32±4 pg/ml respectively in L. major infected BMMs. Less TNF-α was 167 
generated when the chitosan concentration was increased to 133.3 µg/ml and above.  168 
Lipopolysaccharides from Escherichia coli O26:B6 (LPS; positive control) stimulated 169 
TNF-α production in both uninfected and infected BMMs after a 24 h incubation period 170 
at a significantly higher level than chitosan (p < 0.05 by t-test). Our results indicated that 171 
HMW chitosan activated M1 macrophages.   172 
 173 
Effects of HMW chitosan on the production of ROS by BMMs at pH = 6.5  174 
ROS plays an important role in the killing of intracellular amastigotes (6, 38, 39) 175 
therefore, we measured ROS production by BMMs stimulated by HMW chitosan. HMW 176 
chitosan (at concentrations 14.8, 44.4 and 133.3 µg/ml) increased the production of 177 
ROS (indicated by H2DCFDA fluorescence) after 4 h of incubation but did not stimulate 178 
ROS after 8 h of incubation (Table S1). Other concentrations of HMW chitosan (1.64, 179 
4.9 and 400 µg/ml) did not stimulate BMMs to produce ROS after 4 h or 8 h of 180 
incubation. 181 
 o
n
 January 7, 2020 at LO
NDO
N SCHO
O
L O
F HYG
IENE & TRO
PICAL M
EDICINE
http://aac.asm
.org/
D
ow
nloaded from
 
 10 
The ROS dose response in both uninfected and infected BMMs was bell-shaped – 182 
similar to that seen with TNF-. Increasing chitosan concentration from 14.8 to 44.4 183 
μg/mL increased ROS production, after which further increase concentration reduced 184 
ROS production. In addition, ROS production by BMMs was significantly decreased (p < 185 
0.05 by t-test) by infecting the cells with L. major as shown in Fig. 2. 186 
We found that HMW chitosan had an in vitro stimulatory effect on BMMs ROS 187 
production after 4h of incubation. We therefore investigated whether this ROS plays any 188 
role in the activity of HMW chitosan against intracellular amastigotes. For these 189 
experiments, the 4 h post treatment time point was taken because ROS peaked at this 190 
point in BMMs in response to chitosan treatment at a time when chitosan does not 191 
induce NO in BMMs (ibid).  Scavenging of ROS by the ROS scavenger, 5mM N-acetyl-192 
L-cysteine (NAC), had no significant impact on the activity of chitosan against 193 
intracellular amastigotes (p > 0.05 by t-test) – see Fig. 3. The ROS scavenger caused a 194 
complete scavenging of ROS production after 4 h (Table S2) and had no cytotoxicity 195 
against KB cells or leishmanicidal activity against L. major amastigotes (data not 196 
shown). Even though chitosan stimulated ROS production it did not play a role in the 197 
anti-leishmanial activity of chitosan. 198 
  199 
Effects of HMW chitosan on the production of NO by BMMs at pH = 6.5 200 
NO plays an important role in the killing of intracellular amastigotes (6, 38, 39) therefore, 201 
we measured NO production by BMMs stimulated by HMW chitosan. We showed that 202 
chitosan did not have a stimulatory effect on BMM NO production after 4 h of incubation 203 
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 11 
(Table S3). However, after a 24 h incubation, HMW chitosan at pH=6.5 had a 204 
stimulatory effect on BMMs NO production in a clear bell-shaped dose dependent 205 
manner (Figure 4). HMW chitosan at concentrations of 14.8, 44.4 and 133.3 μg/mL 206 
induced both uninfected and infected BMMs to produce NO (at 14.9± 0.3, 34±1.2 and 207 
11±1 μM respectively in uninfected BMMs and 11 ±1, 26 ± 2.5 and 8 ± 1.2 μM 208 
respectively in infected BMMs), NO being highest at 44.4 μg/ml. While other 209 
concentrations of HMW chitosan (1.64, 4.9 and 400 µg/ml) did not stimulate BMMs to 210 
produce NO after 24 h of incubation. 211 
 LPS caused significantly higher NO production compared to HMW chitosan (p < 0.05 212 
by t-test) in both uninfected and infected BMMs. The levels of NO produced by L. major 213 
infected BMMs exposed to LPS (positive control) or HMW chitosan were significantly 214 
lower than levels produced by uninfected BMMs (p < 0.05 by t-test) (Fig 4). 215 
As HMW chitosan had an in vitro stimulatory effect on BMM NO production after 24h of 216 
incubation, we investigated further whether NO has any role in the activity of HMW 217 
chitosan against intracellular amastigotes. Inhibition of NO production by the NO 218 
inhibitor NG-methyl-L-arginine acetate salt (L-NMMA) at 0.4mM, had no significant 219 
influence on the activity of chitosan against intracellular amastigotes (p > 0.05 by t-test) 220 
(Fig. 5), although the NO inhibitor did cause a complete inhibition of NO production 221 
(Table S2) after 24 h and had no cytotoxicity effects against KB cells and no 222 
leishmanicidal activity against intracellular L. major amastigotes (data not shown). Even 223 
though chitosan stimulated NO production it did not play a role in the anti-leishmanial 224 
activity of chitosan. 225 
 226 
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 12 
Cellular uptake of HMW chitosan and inhibition of endocytosis 227 
We found that the activation of M1 macrophages by HMW chitosan did not play a role in 228 
its activity against intracellular amastigotes. Therefore, we investigated whether the anti-229 
leishmanial effects of HMW chitosan against intracellular amastigotes after 4 h and 24 h 230 
exposure were dependent on the direct activity of chitosan following its entry into the 231 
macrophages at pH 6.5.  No significant difference was observed in the activity of 232 
chitosan against intracellular amastigotes when it was added after prior phagocytosis 233 
inhibition with cytochalasin D (Figure 6, p > 0.05 by t-test). In contrast, dynasore (an 234 
inhibitor of pinocytosis, a clathrin-mediated endocytosis (CME) inhibitor) did significantly 235 
affect chitosan mediated parasite killing at pH = 6.5 (Fig. 6, p< 0.05 by t-test). The same 236 
activity was seen at pH 7.5. – see Fig 6, panel C.  The two inhibitors had no cytotoxicity 237 
against KB-cells or activity against intracellular L. major amastigotes at the 238 
concentrations used. Pinocytosis (CME) played a critical role in the efficacy of HMW 239 
chitosan against intracellular amastigotes.  240 
 241 
Fluorescence microscopy of the uptake of chitosan by macrophages 242 
Rhodamine-labelled chitosan was used to track the delivery of chitosan to the 243 
parasitophorous vacuole (PV) of Leishmania infected macrophages. Fig. 7 illustrates the 244 
cellular uptake of chitosan by L. major-GFP- or L. mexicana-GFP- infected BMMs after 245 
4 h and 24 h rhodamine-labelled chitosan exposure. There was co-localization of 246 
chitosan and intracellular amastigotes after 4 h and 24 h with nMDP colour index 0.7 247 
and 1 respectively (see nMDP material and methods). The uptake of chitosan increased 248 
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 13 
in a time-dependent manner. Fig 7 (Panels D and E) shows this uptake after 4 h and 24 249 
h respectively, and the accumulation of chitosan in PVs (shown as yellow that indicates 250 
co-localization of rhodamine and GFP). Fig 7 (Panel F) also shows that the inhibition of 251 
pinocytosis (CME) with dynasore prevented the uptake of chitosan with a negative 252 
nMDP colour index that represents no co-localization of chitosan and amastigotes.  This 253 
is also supporting evidence for the uptake by pinocytosis as seen in Fig 6. 254 
 255 
Discussion 256 
The literature on the anti-leishmanial activity of chitosan and its derivatives is limited, 257 
especially pertaining to its mechanism(s) of action (19, 40, 41). In this study, we 258 
assessed the anti-leishmanial activity of various forms of chitosan, including low, 259 
medium and high molecular weight chitosan, and chitosan derivatives. Chitosan 260 
derivatives are generally produced by chemical modification of the amino or hydroxyl 261 
groups of chitosan for the optimization of the physicochemical properties. We found that 262 
chitosan and its derivatives had minimal cytotoxicity against KB-cells with LD50 values 263 
≥750 µg/ml in RPMI 1640 at pH 7.5 or 6.5. This data supports previous reports of 264 
chitosan’s low cytotoxicity against CCRF-CEM (human lymphoblastic leukaemia) and 265 
L132 (human embryonic lung) cells with similar LD50 values (42, 43).  266 
We determined that a lower pH 6.5, compared to pH 7.5, enhanced, by 7-20, times the 267 
anti-leishmanial activity of chitosan and its derivatives against L. major and L. mexicana 268 
promastigotes and amastigotes. This higher activity of chitosan at the lower pH 6.5 269 
could be due to its greater ionisation (protonation of the amino groups; pKa of 270 
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chitosan≈6.3). The greater positive charge could increase the chitosan antimicrobial 271 
activity by interacting with the negatively charged microbial membrane – in accordance 272 
with the first postulated mechanism of antimicrobial activity described in the Introduction 273 
(18, 19). A higher chitosan activity at lower pH (pH ≈ 5) has previously been reported 274 
against Escherichia coli and Salmonella typhimurium (44, 45). 275 
 Our study is the first to show the pH dependence of the anti-leishmanial activity of 276 
chitosan and its derivatives and could explain why literature reports of the anti-277 
leishmanial activity of chitosan have shown such variability, with EC50 values ranging 278 
from 70 to 240 μg/ml against L. infantum, L. amazonensis and L. chagasi promastigotes 279 
and amastigotes (29, 30, 31, 32, 33, 34). For example, in one study, the EC50 of 280 
chitosan against L. infantum amastigotes (in PEMs) in RPMI 1640 medium was 100.81 281 
μg/ml, but the pH at which the experiment was conducted was not mentioned (29). 282 
Influence of pH was also seen when the anti-leishmanial activity of chitosan (of the 283 
different molecular weights) and chitosan derivatives were compared. While the different 284 
chitosans and derivatives showed minor differences in their anti-leishmanial activity at 285 
pH 7.5, the derivatives were 3 to 5 times less active than the HMW, MMW, LMW and 286 
fungal chitosan at lower pH 6.5. This reduced activity could be due to the lower number 287 
of amino groups on the chitosan derivatives (see Fig 8). These derivatives are more 288 
soluble at a higher pH and have similar activity to chitosan, but at a lower pH the higher 289 
protonation of the chitosan improves the anti-leishmanial activity significantly (46, 47). 290 
Carboxymethyl chitosan had no anti-leishmanial activity - most of the amino groups on 291 
this derivative have been substituted by carboxymethyl moieties making the molecule 292 
negatively charged (48) . 293 
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The higher anti-leishmanial activity of HMW chitosan compared to MMW and LMW 294 
chitosan mirrors its greater antibacterial activity in another study against Escherichia 295 
coli, Pseudomonas aeruginosa and Staphylococcus aureus (49). HMW has a long 296 
chain, and therefore more glucosamine units, and possesses more amino groups (Fig 8) 297 
resulting in more protonated groups (-NH3+) than MMW and LMW(49) which could 298 
explain its greater potency. 299 
We also showed that the anti-leishmanial activity of chitosan is significantly greater 300 
against L. major infected PEMs or BMMs compared to differentiated THP-1 cells in the 301 
order PEMs>BMMs>THP-1 cells underlining the need to take the host cell into 302 
consideration when conducting similar experiments(50).  303 
 In order to understand the potential anti-amastigote mechanism(s) of chitosan, we 304 
investigated whether the activity of HMW chitosan against the intracellular amastigotes 305 
was via direct uptake into the host cell and localisation in the parasitophorous vacuole 306 
or  indirectly via the activation of M1 macrophages, given that the cellular immune 307 
responses in cutaneous leishmaniasis play a critical role in self-cure (51, 52).                                                                                                                                                                                                                                 308 
The activation of M1 macrophages by Th1 lymphocyte subpopulation, which produces 309 
different cytokines, primarily IFN-γ and TNF-α, is crucial for the killing of the intracellular 310 
Leishmania via the triggering of an oxidative burst and therefore, the host cells increase 311 
the production of ROS and NO which are responsible for killing of the parasite (38, 39). 312 
We found that HMW chitosan stimulated TNF-α production by macrophages and this 313 
would be expected to be an indicator of an M1 macrophage that would have greater 314 
leishmanicidal activity. Our results show that chitosan stimulated BMMs ROS production 315 
with a peak after 4 h and led to a significant increase in the TNF-α and NO production 316 
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after 24 h in a bell-shaped response. Similar findings have been reported showing that 317 
HMW chitosan had in vitro stimulatory effect on NO production in PEMs (from male rats) 318 
(25) and LMW chitosan stimulated RAW264.7 macrophage TNF- α production (24). 319 
Another study demonstrated that LMW chitosan induced ROS production in an 320 
epithelial, human breast cancer cell line (53). The bell-shaped responses are consistent 321 
with a study that showed that chitosan stimulated NO and TNF-α production in 322 
peritoneal macrophages  in a dose-dependent manner and their levels tended to 323 
decrease at higher concentrations of chitosan (320μg/ml )(54). This type of response 324 
has also been reported previously for tucaresol for both, its immunomodulatory and 325 
activity against experimental L. donovani infections, albeit at lower doses (55).  Despite 326 
the observed chitosan-induced ROS and NO production, there was no evidence that 327 
this contributed to the anti-leishmanial activity in our study – the inhibitors that we used 328 
to suppress their production had no effect on the ability of chitosan to kill intracellular 329 
Leishmania amastigotes (Figs 3 and 5).  This led us to investigate the cellular uptake of 330 
HMW chitosan and its relationship to the anti-leishmanial activity.   331 
The uptake of the large charged molecule HMW chitosan has not been systematically 332 
studied before and there is no clear evidence of its penetration of cell membranes or of 333 
its uptake mechanism. Macrophages are known to take up extracellular materials and 334 
plasma by endocytosis. Endocytosis mainly occurs via two different cellular uptake 335 
mechanisms: pinocytosis or phagocytosis, where pinocytosis is fluid-phase endocytosis 336 
and phagocytosis is the process of engulfing large particles (56). Inhibition of 337 
pinocytosis (CME) significantly reduced the anti-leishmanial activity of HMW chitosan. 338 
Therefore, in our study pinocytosis (CME) was considered to be the main mechanism 339 
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for the uptake of HMW chitosan by BMMs, indicating a direct anti-leishmanial effect of 340 
this molecule against amastigotes. Other studies have previously reported pinocytosis 341 
as the pathway for the uptake of chitosan of different molecular weights by HEK293 342 
epithelial cells  (57). The fluorescence imaging in our study showed that in BMMs HMW 343 
chitosan is taken up into the parasitophorous vacuole (PV) where the Leishmania 344 
parasites reside, with the labelled chitosan being internalized within 4 h and increasing 345 
up to 24 h later. This is consistent with another study where rhodamine isothiocyanate- 346 
chitosan (RITC-chitosan 98-10 K) was found to be directly delivered to the U937 347 
macrophage lysosome after 24 h (58). The accumulation of chitosan in the PV might be 348 
due to chitosan's relatively high pKa of 6.3, making it more soluble and protonated in the 349 
acidic contents of the vacuole. This is consistent with a study using bafilomycin to inhibit 350 
acidification and prevent chitosan accumulation within macrophages (58). 351 
In summary, our studies indicate that chitosan and its water-soluble derivatives showed 352 
anti-leishmanial activity against both L. major and L. mexicana promastigotes and 353 
amastigotes in a pH dependent manner. At pH 6.5 HMW chitosan is more active than 354 
MMW and LMW chitosan and chitosan derivatives, in particular those where the amino 355 
groups are substituted. In addition, HMW chitosan activated M1 macrophages, 356 
stimulating them to produce NO and ROS. However, the anti-leishmanial activity of 357 
chitosan was not due to such immune activation, as an NO inhibitor and a ROS 358 
scavenger failed to reduce the anti-leishmanial activity. Instead, the anti-leishmanial 359 
activity was related to direct uptake of chitosan into the parasitophorous vacuole by 360 
pinocytosis (CME). HMW chitosan demonstrated effective in vitro anti-leishmanial 361 
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activity with minimal cytotoxicity and future work will focus on in vivo studies, 362 
formulations and routes of administration.  363 
 364 
Materials and methods 365 
 366 
(i)  Drugs and chemicals 367 
Stocks of amphotericin B deoxycholate (5.2 mM [aq]) (Fungizone; Gibco, UK) were 368 
prepared, aliquoted, and kept at -20°C until use. Chitosan with three different molecular 369 
weights and its derivatives were used and are summarised in Table 1 (28, 59, 60, 61). 370 
Solutions of chitosan and derivatives were prepared by dissolving 1 g in 100 ml of 1% 371 
(v/v) acetic acid solution at room temperature with continuous stirring for 24 h until a 372 
clear solution was obtained. The pH of the solution was adjusted to approximately 6 by 373 
adding sodium hydroxide 2N (NaOH, Sigma, UK) solution with a pH meter (Orion Model 374 
420A). The chitosan solutions were autoclaved (121 °C; 15 mins). Phosphorylcholine 375 
substituted chitosan was kindly provided by Prof F Winnik (Montreal University, Canada) 376 
generated through reductive amination of PC-glyceraldehyde with primary amines of 377 
deacetylated chitosan (57kD). Percentage of substitution was controlled and determined 378 
by NMR (28). Chitosan pKa is approximately 6.3 and therefore, the approximate 379 
ionisation degree of chitosan is a 61% and 6% at pH 6.5 and 7.5 respectively. 380 
  381 
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(ii) Ethics statement.  382 
All animal work is carried out under a UK Home Office project licence according to the 383 
Animal (Scientific Procedures) Act 1986 and the new European Directive 2010/63/EU. 384 
The Project Licence (70/8427) has been reviewed by LSHTM Animal Welfare & Ethical 385 
Review Board prior to submission and consequent approval by the UK Home Office.  386 
(iii) Cell lines  387 
Preparation of macrophages 388 
- Peritoneal mouse macrophages (PEMs) were obtained from 8-12 week old 389 
female CD1-mice (Charles River Ltd, UK). Two ml of a 2% (w/v) starch solution in 390 
phosphate buffered saline (PBS, Sigma, UK) was injected intraperitoneally (IP). 391 
After 24 h, the animal was sacrificed and the PEMs were harvested by peritoneal 392 
lavage with cold RPMI 1640 medium (Sigma, UK) containing 200 units penicillin 393 
and 0.2 mg streptomycin/mL (PenStrep; Sigma, UK). Subsequently, PEMs were 394 
centrifuged at 450 g at 4°C for 15 min and then the pellet was resuspended in 395 
RPMI 1640 with 10% (v/v) heat-inactivated fetal calf serum (HiFCS; Gibco, UK).  396 
- Bone marrow-derived macrophages (BMMs) were obtained from femurs of 8-12 397 
week old female BALB/c mice (Charles River Ltd). Briefly, the bone marrow cells 398 
were carefully flushed from the bone with Dulbecco’s Modified Eagle’s Medium 399 
(DMEM; Thermofisher, UK) with 10% (v/v) HiFCS, 100 U/mL penicillin and 100 400 
mg/mL streptomycin (Sigma, UK). Cells were pelleted by centrifugation (450 g, 401 
10 min) and re-suspended in 10ml DMEM with 10% (v/v) HiFCS and human 402 
macrophage colony stimulating factor 50ng/ml (HM-CSF; Thermofisher, UK). 403 
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After plating out in T175 flasks (Greiner Bio-One, Stonehouse, UK), BMMs were 404 
kept at 37°C, 5% CO2 for 7-10 days after which they were harvested, counted 405 
and used. 406 
- THP-1 cell is a human leukemic monocyte-like derived cell line. THP-1 cells were 407 
cultured in RPMI 1640 medium supplemented with L-glutamine and 10% HiFCS. 408 
THP-1 cells were incubated in RPMI 1640 plus 10% (v/v) HiFCS and 20 ng/mL 409 
phorbol 12-myristate 13-acetate (PMA; Sigma, UK) at 37°C and 5% CO2 for 72 h 410 
to induce maturation transformation of these monocytes into adherent 411 
macrophages (50). 412 
Human squamous carcinoma (KB) cells are adherent cells derived from epidermal 413 
carcinoma from the mouth. KB cells were cultured in RPMI 1640 medium 10% HiFCS. 414 
The number of cells and macrophages was estimated by counting with a Neubauer 415 
haemocytometer by light microscopy (x 400 total magnification). 416 
(iv)  Parasites 417 
Four Leishmania species; two GFP labelled species (L. major (MHOM/SU/73/5ASKH) 418 
and L. mexicana (MNYC/BZ/62/M379), kindly donated by Dr. G Getti (University of 419 
Greenwich, UK) were used for the fluorescence microscope study. They were cultured 420 
in Schneider’s insect medium (Sigma, UK) with 23% (v/v) HiFCS, 1× penicillin-421 
streptomycin-glutamine (Gibco-Invitrogen) and supplemented with 700 μg/mL G418 (an 422 
aminoglycoside antibiotic, Sigma, UK).  L. major (MHOM/SA/85/JISH118) and L. 423 
mexicana (MNYC/BZ/62/M379) were used for other experiments as described, minus 424 
the G418. Promastigotes were incubated at 26°C, maximum passage number used = 7. 425 
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(v)  In vitro cytotoxicity assays 426 
Re-suspended KB cells (4 x 104 /100uL) were allowed to adhere to the bottom of 96-427 
well plate overnight and then exposed to specific concentrations of the compounds for 428 
72 h at 37°C and 5% CO2 incubator. Podophyllotoxin (Sigma, UK) was included as a 429 
positive control at a starting concentration of 0.05 μM. Cytotoxicity was evaluated by a 430 
cell viability assay using the resazurin sodium salt solution (AlamarBlue, Sigma, UK) 431 
which was prepared according to the manufacturer’s instructions. 20μL of the resazurin 432 
solution was added to each well of the plates and fluorescence (cell viability(62)) was 433 
measured over a period of 1 to 24 h using a Spectramax M3 plate reader (EX/EM 530 / 434 
580 nm and 550 nm cut off). Results were expressed as percentage inhibition = (100 – 435 
x)% viability (means ± standard deviation ). Cytotoxicity was evaluated in RPMI 1640 436 
at two pH values (at normal pH of RPMI 7.5 and at a lower pH 6.5). The pH of RPMI 437 
1640 was reduced from 7.5 to 6.5 by adding 0.05M acidic buffer, 2-N-morpholino 438 
ethanesulfonic acid (MES, Sigma, UK). RPMI 1640 plus MES (0.05M) at pH=6.5 did not 439 
show any cytotoxicity to KB-cells. 440 
(vi) In vitro 72 h activity of chitosan and its derivatives against extracellular 441 
L. major and L. mexicana promastigotes 442 
Promastigotes in RPMI 1640 medium were tested while in the exponential growth 443 
phase. The promastigotes were diluted to a density of 5x106 promastigotes/ml and then 444 
exposed to different concentrations of (HMW, MMW, and LMW) chitosan, chitosan 445 
derivatives and Fungizone (positive control) in sterile 96-well flat bottom culture plates 446 
for 72 h at 26°C. The activity of the compounds against promastigotes was evaluated 447 
using the Alamar Blue assay as previously described.  pH plays a critical role in the 448 
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solubility and protonation of chitosan, so the activity against promastigotes was 449 
evaluated at two different pH values (pH=7.5 and a lower pH of 6.5 by adding MES). 450 
Results were expressed as percentage inhibition= 100% - x% viability (means ± SD).  451 
(vii) In vitro 72- hour activity of chitosan and its derivatives against 452 
intracellular amastigotes of L. major and L. mexicana 453 
100uL of PEMs culture at 4 ₓ 105 cells/mL, dispensed into each well of a 16-well LabTek 454 
tissue culture slide (Thermo Fisher, UK) at pH 7.5 or pH 6.5 and incubated for 24 h at 455 
37 °C in 5 % CO2. After 24 h, the wells were washed with fresh culture medium to 456 
remove non-adherent cells. Stationary phase, low-passage-number Leishmania 457 
promastigotes were then added at a ratio of 5 :1 PEM. This infection ratio was 458 
previously found to give sufficiently high and reproducible infection levels. Slides were 459 
incubated for another 24h at 34 °C to mimic dermal temperatures in 5 % CO2. Any free, 460 
extracellular parasites were removed by washing the wells with cold culture medium. 461 
One slide was fixed with 100 % methanol for 2 min and stained with 10 % Giemsa for 5 462 
minutes. The number of PEMs infected with Leishmania amastigotes per 100 463 
macrophages was microscopically counted.  All the experiments were conducted at 464 
macrophages infection levels above 80% prior to addition of chitosan.  Chitosan, its 465 
derivatives and Fungizone solutions at a range of concentrations (in quadruplicate) 466 
were added to the wells (100µl) and the slides were incubated for 72 h at 34 °C in 5 % 467 
CO2. After 72 h, the slides were fixed with 100% methanol for 2 min and stained with 468 
10% Giemsa for 5 min. The slides were examined and the % of macrophages infected 469 
was counted. The anti-leishmanial activity of compounds was expressed as percentage 470 
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reduction in infected macrophages compared to untreated control wells (63). RPMI 1640 471 
plus MES (0.05M) with pH=6.5 had no activity against Leishmania amastigotes.  472 
(viii) Influence of the origin of the host cell on the in vitro activity of HMW 473 
chitosan against L. major amastigotes  474 
A further two host cell types, THP-1 and BMMs were infected with Leishmania major 475 
and the activity of HMW chitosan was assessed. THP-1 cells (cultured in RPMI 1640 + 476 
10% HiFCS) and BMMs (cultured in DMEM + 10% HiFCS) were used to assess the 477 
host cell dependence of the anti-leishmanial activity of HMW chitosan(50). The 478 
experiment was conducted as described in section (vii) at pH 6.5.  479 
(ix) The role of HMW chitosan on BMMs activation  480 
We chose BMMs to evaluate the activation effects of HMW chitosan and to study the 481 
cell uptake of chitosan as this macrophage population is more homogenous than PEMs 482 
and THP-1 cells (64); both PEMs and BMMs have been reported to have a similar acidic 483 
pH ≈ 5.5 of parasitophorous vacuoles of L. amazonensis infected PEMs and BMMs (65, 484 
66, 67). 100uL of BMMs (4 x 105/ml) in DMEM at pH=6.5 were dispensed into each well 485 
of 96 well plates (standard clear plates for nitric oxide assay and black wall/clear bottom 486 
plates for ROS and TNF-α assay) and incubated for 24 h at 37 °C in 5 % CO2. Plates 487 
were washed with DMEM to remove non-adherent macrophages. L. major at 1:5 ratio (5 488 
parasites per host cell) was then added to the wells and the plates were incubated for 489 
24 h at 34 °C in 5 % CO2 to allow infection of the adherent macrophages. After 24 h 490 
incubation with macrophages, infection rate more than 80%. The effects of HMW 491 
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chitosan on BMMs activation was determined by quantifying the release of TNF-α, ROS 492 
and NO, as described below at pH 6.5.  493 
A. Measurement of TNF-α                                                           494 
HMW chitosan at concentrations of 1.64, 4.9,14.8, 44.4, 133.3 and 400 µg/ml was 495 
added to infected and uninfected macrophages (section x) and the plates were 496 
incubated for 4, 24 h at 34°C in 5% CO2 . Lipopolysaccharides from Escherichia coli 497 
O26:B6 (LPS, 100ng/ml; Sigma, UK) was used as a positive control and inducer. TNF-α 498 
release by the BMMs was measured using a mouse TNF-α ELISA kit (ab208348, 499 
abcam, UK) according to the manufacturer's instructions using a Spectramax M3 500 
microplate reader (wavelength 450 nm) .  501 
B. Measurement of ROS  502 
ROS was measured using a 2′,7′–dichlorofluorescein diacetate (DCFDA, cellular 503 
reactive oxygen species detection assay kit, abcam, UK). Uninfected and infected 504 
macrophages were treated with 25 µM DCFDA in PBS for 45 min at 37°C and then 505 
washed once in the buffer. The cells were cultured at 34°C in 5% CO2 for 0.5, 1, 2, 4,8 506 
and 24 h, with 1.64, 4.9,14.8, 44.4, 133.3 and 400 µg/ml of HMW chitosan or in the 507 
presence of H2O2 (25mM) (Thermofisher, UK) as a positive control in DMEM + 10% 508 
HiFCS (pH=6.5) in quadruplicate wells. In some experiments, cells were pre-treated 509 
with a selective inhibitor of ROS, N-acetyl-L-cysteine (NAC, 5mM; Sigma, UK), for 2 h 510 
before the addition of the inducer or chitosan.  At 0.5, 1, 2, 4, 8 and 24 h the plates were 511 
read, using a Spectramax M3 microplate reader (Ex=485nm, Em=535nm).  512 
C. Measurement of NO  513 
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NO was measured using Griess reagent (Thermofisher, UK). HMW chitosan at 514 
concentrations of 1.64, 4.9,14.8, 44.4, 133.3 and 400 µg/ml  was added to infected and 515 
uninfected macrophages and the plates were incubated at 4, 24 h at 34°C in 5% CO2. 516 
LPS (100ng/ml) was used as a positive control. In some experiments, cells were pre-517 
treated with selective inhibitor of nitric oxide with NG-methyl-L-arginine acetate salt (0.4 518 
mM, L-NMMA; Sigma, UK) for 2 h before the addition of LPS. NO was quantified 519 
according to the kit protocol, Briefly, 150μl of the cell culture supernatants (particulates 520 
were removed by centrifugation) was mixed gently with 150μl of the Griess reagent in a 521 
96 well plates and the mixture was incubated for 30 minutes at room temperature. The 522 
absorbance was measured using a Spectramax M3 plate reader (wavelength 548 nm). 523 
Sodium nitrite (Sigma, UK) at different concentrations was used to create a standard 524 
curve(68).  525 
(x) Uptake of chitosan by macrophages 526 
The uptake of HMW chitosan was evaluated using two methods. The first method used 527 
two endocytosis inhibitors; cytochalasin D (1µg/ml , Sigma, UK) which is a phagocytosis 528 
inhibitor and dynasore (30 µg/ml, Sigma, UK) which inhibits pinocytosis (clathrin-529 
mediated endocytosis (CME) by blocking GTPase activity of dynamin) (69, 70, 71) . The 530 
second method used dynasore and rhodamine-labelled chitosan (MW 200 kDa, 531 
Creative PEGWorks, USA) to track cellular uptake of chitosan over time by fluorescence 532 
microscopy. 533 
 534 
 535 
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A. Activity of chitosan after inhibition of the endocytic pathway of BMMs 536 
100uL of BMMs culture (4 x 105/ml) in DMEM at pH 6.5 or pH=7.5 were dispensed into 537 
each well of 16-well LabTek culture slides and were infected with stationary phase L. 538 
major promastigotes. Some of the infected BMMs were pretreated with dynasore (30 539 
µg/ml) or cytochalasin D (1µg/ml) for two hours. Subsequently, HMW chitosan was 540 
added to each well at concentrations of 1.64, 4.9,14.8, 44.4, 133.3 and 400 µg/ml and 541 
macrophages were incubated for 4 or 24 h at 34 °C in 5 % CO2.  After each point, the 542 
slides were examined as described in section (vii).The inhibition activity of the uptake 543 
(phagocytosis or pinocytosis) of the two inhibitor was evaluated by using a fluorescence 544 
plate reader, by using fluorescent latex beads and pHrodo™ Red dextran  (72). We 545 
showed that cytochalasin caused 94 and 84% phagocytosis inhibition of fluorescent 546 
latex beads (Sigma-Aldrich, UK) after 4 h and 24 h respectively and dynasore caused 547 
95 and 90% pinocytosis inhibition of pHrodo™ Red dextran (Mw= 10,000 MW, Thermo 548 
Fisher, UK) after 4h and 24h respectively (Table S6).   549 
B. Microscopic imaging of the cellular uptake of rhodamine-labelled chitosan 550 
The qualitative characterisation of chitosan uptake of cells was carried out by wide field 551 
microscopy (Nikon Ti-E inverted microscope). Briefly, after deriving BMMs, 500μl of the 552 
BMMs (in DMEM plus 10% HiFCS at pH 6.5, 4 x 10 4 macrophages per ml) was seeded 553 
on each well of a 4-well LabTek tissue culture slide (Thermo Fisher, UK) and incubated 554 
for 24h at 37°C in 5% CO2. Subsequently, 5 µg/mL Hoechst 33342 stain (Ex/Em = 555 
350⁄461 nm, Thermofisher, UK) as a nuclear dye was added and the slides were 556 
incubated for 30 min at 37°C in 5% CO2. The macrophages were washed with PBS, L. 557 
major-GFP of L. mexicana-GFP was then added, at a ratio of 10:1 and further incubated 558 
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for 24h at 34°C in 5% CO2 (We used 10:1 ratio not 5:1 as previously as at this 559 
experiment different species of L. major-GFP and L. mexicana-GFP were used and the 560 
ratio 10:1 was sufficient to obtain a high infection rate). Macrophages were then washed 561 
with PBS and 500 µl of LysoTracker® far Red (50 nM, Ex/Em;647/668nm; Thermo 562 
Fisher, UK) was added to each well. The labelled, infected macrophages were then 563 
exposed to 30 µg/ml rhodamine-labelled chitosan (MW 200kDa, Creative PEGWorks, 564 
USA) in 500 µl of fresh DMEM plus 10% HiFCS pH 6.5 and incubated for 4  h and 24h 565 
at 37°C with live imaging at each time point.  In some experiments, infected BMMs were 566 
pre-incubated with dynasore 30 µg/ml for 2 h before adding rhodamine-labelled 567 
chitosan. All the images were collected using a Nikon Ti-E inverted microscope 568 
equipped with (63x objective) using Nikon Elements software. Three images for each 569 
experiment were then analysed using ImageJ software. The degree of correlation 570 
between pixels in the red and green channels was assessed by the Colocalization 571 
Colormap plugin in the ImageJ software. This plugin enables quantitative visualisation of 572 
colocalization by calculating the normalized mean deviation product (nMDP) in a colour 573 
nMDP scale (from -1 to 1): negative refers (cold colours) to no colocalization while 574 
indexes more than 0 (hot colours) display colocalization and the higher number refers to 575 
more colocalization (73, 74).  576 
(xi) Statistical analysis. 577 
Dose-response curves and EC50 values were calculated using GraphPad Prism 578 
version 7.02 software and the corresponding sigmoidal dose-response curves were 579 
established by using a nonlinear fit with variable slope models. Results represent means 580 
± SD. EC50 values were compared by using extra-sum-of-squares F tests. t test was 581 
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used to compare differences between means of two or more groups respectively and p 582 
values of 0.05 were considered statistically significant. 583 
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TABLE 1 In vitro activity of chitosan and its derivatives against promastigotes at two pH values  
Compound 
pH=7.5 * pH=6.5*,** 
L. major L. mexicana L. major L. mexicana 
EC50 µg/ml EC90 µg/ml EC50 µg/ml EC90 µg/ml EC50 µg/ml EC90 µg/ml EC50 µg/ml EC90 µg/ml 
Fungizone 0.05± 0.01 0.2± 0.02 0.14± 0.01 0.3± 0.03 0.07± 0.02 0.3± 0.1 0.13± 0.07 0.3± 0.02 
HMW chitosan 105± 12 1549± 525 140± 12 2187± 928 5.9± 0.5 37± 9 10.4± 1.6 98± 33 
MMW chitosan 113± 9 1277± 580 150± 12 2223± 681 6.2± 0.3 43± 8 10.9± 1.4 96± 27 
LMW chitosan 118± 11 1238± 582 157± 13 2225± 723 6.7± 0.3 40± 8 10.2± 1.5 84± 28 
Fungal chitosan 118± 11 1228± 560 150± 13 1991± 580 6.2± 0.3 42± 6 10.5± 1.3 61± 17 
Chitosan Oligosaccharide 153± 15 1680± 506 190± 20 2366± 461 62.5± 4 446± 92 77± 2.7 452± 36 
Chitosan Oligosaccharide- lactate 98± 9 1226± 130 125± 14 765± 83 14± 0.1 135± 2 23± 1.4 311± 25 
Chitosan HCL 96± 7 1189± 211 110± 24 746± 169 13.2± 1 118± 34 20.8± 2.4 264± 61 
PC1-CH(Phosphorylcholine substituted chitosan) 111± 20 1875± 230 176± 14 2832± 412 19.9± 2.8 187± 90 32± 2.2 328± 48 
PC2-CH 104± 6 1485± 259 170± 8 2744± 377 16.5± 2.7 138± 49 28± 2.4 296± 53 
PC3-CH 119± 19 1860± 365 187± 16 3175± 580 23.3± 2.5 218± 44 37± 2.5 442± 65 
Carboxymethyl chitosan 
 
 
 
No activity up to 400 µg/ml 
 
Experiments were conducted in triplicate cultures, data expressed as mean +/- SD (experiment was reproduced further two times with confirmed similar data not 
shown). *Statistically significant differences were found for the EC50 values of chitosan and its derivatives at pH=6.5 and pH=7.5 (p<0.05 by using t-test). ** L. 
major promastigotes were significantly more susceptible to chitosan and derivatives than L. mexicana ((p<0.05 by an extra sum-of-squares F test)). 
Amphotericin B deoxycholate (Fungizone) was used as a positive control. Both RPMI alone pH 6.5 and chitosan solvent did not show any activity against 
promastigotes.   
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TABLE 2 In vitro activity of chitosan and its derivatives against amastigotes infecting PEMs and their cytotoxicity  
Compound 
pH 7.5* 
 
pH 6.5* 
 
pH 6.5** 
L. major L. mexicana L. major L. mexicana KB cells 
EC50 µg/ml EC90 
µg/ml 
EC50 
µg/ml 
EC90 µg/ml EC50 
µg/ml 
EC90 
µg/ml 
EC50 
µg/ml 
EC90 µg/ml LD50 
µg/ml 
LD90 µg/ml 
Fungizone 0.07± 0.01 0.13± 0.05 0.19± 0.05 1.5± 0.2 0.06± 0.01 0.11± 0.06 0.18± 0.06 1.7± 0.3 58± 8 190± 9 
HMW chitosan 98± 6 
1635 ± 
245 
119 ± 9 
1804 ± 
304 
11.4± 1 69± 18 15.4±2 103± 28 752± 90 3022± 366 
MMW chitosan 103± 8 
1652 ± 
287 
125± 10 
1793 ± 
323 
12.9± 1 81± 18 16.3±2 122± 34 758± 89 3019± 400 
LMW chitosan 102 ± 7 
1651 ± 
282 
125± 10 
1795 ± 
320 
12.1± 1 74± 14 16.1±2 116.6± 33 803± 90 3088± 420 
Fungal chitosan 102 ± 7 1650± 276 124 ± 9 
1796 ± 
316 
12.6±3 92± 27 16.9 ±2 144± 44 759± 91 3134± 380 
Chitosan Oligosaccharide 145 ± 12 
2473 ± 
500 
175 ± 14 
2543 ± 
505 
73 ± 4 260± 32 86.2±6 288±39 765± 93 3232± 400 
Chitosan Oligosaccharide- 
lactate 
93 ± 7 
1957 ± 
174 
120 ± 9 
2365 ± 
239 
39± 1 201± 16 47±2 245± 23 754± 92 3058± 390 
chitosan HCl 97 ± 11 2080± 516 121 ± 15 
2402 ± 
667 
40± 2 210± 23 47.9±3 243± 33 781± 92 3589± 405 
PC1-CH 144 ± 10 
1292 ± 
217 
169 ± 12 
1365 ± 
212 
68± 3 246± 26 81.7±6 274±38 756± 93 3364± 398 
PC2-CH 133 ± 6 
1005 ± 
194 
159 ± 6 
1705 ± 
170 
60± 3 202± 22 71.9±5 237±36 800± 92 3709± 410 
PC3-CH 163 ± 11 
1052 ± 
144 
187± 10 
1107 ± 
142 
71± 4 251± 30 83.5±6 286± 41 786± 93 3719± 378 
Carboxymethyl chitosan 
 
No activity up to 400 µg/ml 1184± 99 3999± 500 
 
Experiments were conducted in quadruplicate cultures, data expressed as mean +/- SD (experiment was reproduced further two times with confirmed similar data and 
data not shown). *Statistically significant differences were found between the EC50 values of chitosan and its derivatives at pH=6.5 and pH=7.5 (p<0.05 by using t-test). 
Chitosan and its derivatives had a low cytotoxicity at both pH values (6.5 and 7.5) toward KB-cells and there was no significant difference in the cytotoxicity at these 
two pH values (p <0.05 by t-test).  ** No statistically significant difference was found in LD50 (50% lethal dose) values between three types of chitosan and other 
derivatives against KB-cells (except carboxymethyl chitosan which is the least toxic) (p>0.05 by an extra sum-of-squares F test).  Both RPMI alone pH 6.5 and chitosan 
solvent did not show any activity against amastigotes.   
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TABLE 3 HMW chitosan activity against L. major amastigotes in three different 
macrophage cultures after 72 h at pH 6.5 
 HMW chitosan Fungizone 
Host cell / infection 
rate % at 24 h 
EC50 µg/ml EC90 µg/ml EC50 µM EC90 µM 
PEMs / > 80% 10.31 ± 1.22* 89.07 ± 20.46 0.02 ± 0.004** 0.27 ± 0.07 
BMMs / > 80% 14.60 ± 1.79* 145.7 ± 36.2 0.04 ± 0.005** 0.43 ± 0.1 
THP-1/ > 80% 24.28 ± 2.87* 200.1 ± 48.8 0.08 ± 0.006** 1.15 ± 0.37 
Experiments were conducted in quadruplicate cultures, data expressed as mean +/- SD (experiment 
was reproduced further two times with confirmed similar data and data not shown)*,**  statistically 
significant difference in EC50 values between the three types of cells (chitosan and Fungizone were 
significantly more active in PEMs and BMMs compared with THP-1 cells) (p<0.05 by an extra sum-of-
squares F test). % infection rate gives the percentage of infected macrophages. Both RPMI and DMEM 
alone pH 6.5 and chitosan solvent did not show any activity against amastigotes.   
 821 
TABLE 4 Details of chitosan and its derivatives used in the study 
Compounds Properties Supplier 
HMW (source: crustacean shells) MW=310-375 KDa Sigma, UK 
MMW (source: crustacean shells) MW=190-310 KDa Sigma, UK 
LMW (source: crustacean shells) MW=50-190 KDa Sigma, UK 
Fungal chitosan (white mushroom) MW=110-150 KDa Dr. S Somavarapu 
Chitosan oligosaccharide MW=≤ 5KDa Dr. S Somavarapu 
Chitosan oligosaccharide lactate  
MW=average Mn 5, 
oligosaccharide 60% 
Dr. S Somavarapu 
Chitosan- HCl  MW= 47 - 65 KDa Dr. S Somavarapu 
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Carboxymethyl chitosan  
MW=543.519 Da, 
level of substitution is 
95% 
Dr. S Somavarapu 
PC1-CH (Phosphorylcholine 
substituted chitosan)  
MW=33 KDa, 
PC(mol%)= 30 
Prof F Winnik 
PC2-CH  
MW=108 KDa, 
PC(mol%)= 20 
Prof F Winnik 
PC3-CH  
MW=109 KDa, 
PC(mol%)= 30 
Prof F Winnik 
 822 
 823 
 o
n
 January 7, 2020 at LO
NDO
N SCHO
O
L O
F HYG
IENE & TRO
PICAL M
EDICINE
http://aac.asm
.org/
D
ow
nloaded from
 
 40 
Figures  824 
 
Fig 1 TNF-α production in uninfected and L. major infected BMMs after 24 h of exposure to 
1.64, 4.9,14.8, 44.4, 133.3 and 400 µg/ml of chitosan at pH 6.5. The dose response in both 
uninfected and L. major infected BMMs was bell-shaped. TNF- α production was significantly 
decreased (p < 0.05 by t-test) by infecting the cells with L. major. Experiments were 
conducted in quadruplicate, data is expressed as mean +/- SD (experiment was reproduced 
further two times with confirmed similar data and data not shown). Positive control= BMMs 
treated with LPS 10 µg/ml. Negative control = BMMs not exposed to chitosan. *Initial 
macrophage infection rate was >80% after 24 h. Chitosan solvent did not cause any TNF-α 
production. 
 825 
 
Fig 2 ROS production in uninfected and L. major infected BMMs after 4 h of exposure 
to 1.64, 4.9,14.8, 44.4, 133.3 and 400 µg/ml of HMW chitosan at pH=6.5. High levels 
of ROS were induced by both uninfected and L. major infected BMMs exposed to 
HMW chitosan compared to those that were not (P <0.05 by t-test). Maximum 
production of ROS occurred at 44.4 μg/mL of chitosan. ROS production by L. major 
infected BMMs was significantly lower compared to uninfected cells (p < 0.05 by t-
test). Experiments were conducted in quadruplicate, data is expressed as mean +/- 
SD (experiment was reproduced a further two times with confirmed similar data (not 
shown). Positive control = BMMs treated with H2O2 25 mM (a known ROS inducer). 
Negative control = BMMs not exposed to chitosan. *Initial macrophage infection rate 
was >80% after 24 h. Chitosan solvent alone did not cause any ROS production. 
 826 
 
Fig 3 Activity of HMW chitosan against L. major amastigotes in BMMs* after 4 h, with 
and without ROS scavenger at pH = 6.5. Infected macrophages were pre-incubated 
with 5 mM NAC for 2 h, after which HMW chitosan at concentrations 1.64, 4.9,14.8, 
44.4, 133.3 and 400 µg/ml was added and the cells were incubated for a further 4 h. 
Chitosan activity against intracellular amastigotes was evaluated as described in 
section (vii). Values are expressed as % inhibition of infection relative to untreated 
controls. After 4 h, there was no significant difference in the anti-leishmanial activity of 
chitosan after scavenging of ROS (p >0.05 by t-test). Experiments were conducted in 
quadruplicate, data is expressed as mean +/- SD. Experiment was reproduced further 
two times with confirmed similar data (not shown).  *Initial macrophage infection rate 
was >80% after 24 h. 
 
 827 
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Fig 4 NO production in uninfected and L. major infected BMMs after 24 h of exposure 
to 1.64, 4.9,14.8, 44.4, 133.3 and 400 µg/ml of chitosan at pH = 6.5. The response in 
both uninfected and infected BMMS was bell-shaped in relation to chitosan 
concentration. Maximal production of NO was stimulated by 44.4 μg/mL of chitosan. 
NO production was significantly decreased (p < 0.05 by t-test) when the cells had 
been infected with L. major. Experiment was conducted in quadruplicate cultures, 
data expressed as mean +/- SD (experiment was reproduced a further two times with 
confirmed similar data and data not shown). Positive control = BMMs treated with LPS 
10 µg/ml. Negative control = BMMs not exposed to chitosan.  *Initial macrophage 
infection rate was >80% after 24 h. Chitosan solvent alone did not cause any NO 
production.  
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Fig 5 Activity of HMW chitosan against L. major -infected BMMs* after 24 h in the 
presence or absence of an NO inhibitor at pH = 6.5. Infected macrophages were pre-
incubated with the NO inhibitor L-NMMA (0.4 mM) for 2 h, following which HMW 
chitosan at concentrations 1.64, 4.9,14.8, 44.4, 133.3 and 400 µg/ml was added and 
the cells were incubated for a further 24h.  Chitosan activity against intracellular 
amastigotes was evaluated as described in section (vii). Values are expressed as % 
inhibition of infection relative to untreated controls. After 24h, there was no significant 
difference in the activity of chitosan after inhibition of NO (p >0.05 by t-test). 
Experiment was conducted in quadruplicate cultures, data expressed as mean +/- SD. 
Experiment was reproduced a further two times and confirmed the results (data not 
shown). *Initial macrophage infection rate was >80% after 24 h. 
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Fig 6 Activity of HMW chitosan against L. major infected BMMs* after 4 h, pH=6.5 (A), 
24 h, pH=6.5 (B) and at 24h, pH=7.5 with or without phagocytosis inhibitor or 
pinocytosis (CME) inhibitor. We found that chitosan requires pinocytosis (CME) not 
phagocytosis by BMMs for killing of L. major amastigotes at pH = 6.5 and 7.5. BMMs 
were infected with stationary-phase promastigotes. Some of the infected 
macrophages were pre-incubated with cytochalasin D (phagocytosis inhibitor) or 
dynasore (pinocytosis (CME) inhibitor) and exposed to various concentrations (1.64, 
4.9,14.8, 44.4, 133.3 and 400 µg/ml ) of chitosan for 4 h and 24 h, followed by 
microscopic counting of the number of infected macrophages. There was no 
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significant difference in the activity of HMW chitosan after inhibition of phagocytosis (p 
>0.05 by t-test). In contrast, a significant inhibition of chitosan-mediated parasite 
killing occurred in the presence of dynasore at two pH values (p <0.05 by t-test). 
Values are expressed as % inhibition of infection relative to untreated controls. 
Experiment was conducted in quadruplicate cultures, data expressed as mean +/- 
SD>. Experiment was reproduced a further two times and confirmed the results (data 
not shown). *Initial macrophage infection rate was >80% after 24 h. 
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Fig 7 Fluorescence microscopy images of the cellular uptake of rhodamine-labelled 
chitosan at 4h and 24 h at pH=6.5 by BMMs infected with L. major-GFP (XA) or with 
L. mexicana-GFP (XB). Blue represents the nuclei of BMMs. Green represents 
intracellular amastigotes, red represents labelled chitosan and yellow represents 
merged red chitosan and green Leishmania.  Panels A-F represent the following: 
Infected BMMs unexposed to chitosan after 4 h (panel A) or 24 h (panel B); Infected 
BMMs exposed to chitosan after 4h (panel D) or 24 h (panel E); Infected BMMs 
unexposed to chitosan after 24 h (panel C) and Infected BMMs exposed to chitosan 
and pinocytosis inhibitor (dynasore) after 24 h (panel F) 
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Fig 8  The structure of chitosan (60) and its derivatives, (chitosan HCl, 
carboxymethyl chitosan (61), chitosan oligosaccharide (60), PC-CH (reprinted with 
permission from reference 28) and chitosan oligosaccharide lactate (59) ) 
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